Fundz

Phio Pharmaceuticals Corp. reported raising $14 Million in an initial SEC Form D filing, from an offering of $24.3 Million

PUBLIC · PHIOFeb 16, 2021$14M of $24.3M raised

Amount Raised

$14 Million

$14 Million sold, per SEC Form D (first sale Feb 16, 2021)

Round Type

Venture

King Of PrussiaBiotechnologyHealthcareHealth CareTherapeutics

Who to call at Phio Pharmaceuticals, and when

A new round usually means Phio Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Phio Pharmaceuticals raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Phio Pharmaceuticals, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Phio Pharmaceuticals. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Phio Pharmaceuticals

Location

411 SWEDELAND ROAD

King Of Prussia, Pennsylvania, United States

About

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology makes immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems. Phio was co-founded by Nobel Laureate Craig Mello, who was awarded the Nobel prize in 2006 for his discovery of RNAi, which has broad therapeutic applications. Our founders opened up a whole new field of biology when they discovered RNAi, and we continue their pioneering efforts today through our work with INTASYL. We’re committed to discovering and developing innovative cancer treatments for patients, creating new pathways for a cancer-free future.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Phio Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

4 contacts
Verified contactsBob I., Vice President Strategic Development hidden hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Phio Pharmaceuticals's next move

See what Strategic adds

Phio Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.